Cao Weiping, Liepkalns Justine S, Hassan Ahmed O, Kamal Ram P, Hofstetter Amelia R, Amoah Samuel, Kim Jin Hyang, Reber Adrian J, Stevens James, Katz Jacqueline M, Gangappa Shivaprakash, York Ian A, Mittal Suresh K, Sambhara Suryaprakash
Immunology and Pathogenesis Branch, Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA, USA.
Department of Comparative Pathobiology, Purdue University, West Lafayette, IN 47907, USA.
Vaccine. 2016 Feb 3;34(6):744-9. doi: 10.1016/j.vaccine.2015.12.062. Epub 2016 Jan 4.
Since the first case of human infection in March 2013, continued reports of H7N9 cases highlight a potential pandemic threat. Highly immunogenic vaccines to this virus are urgently needed to protect vulnerable populations who lack protective immunity. In this study, an egg- and adjuvant-independent adenoviral vector-based, hemagglutinin H7 subtype influenza vaccine (HAd-H7HA) demonstrated enhanced cell-mediated immunity as well as serum antibody responses in a mouse model. Most importantly, this vaccine provided complete protection against homologous A/H7N9 viral challenge suggesting its potential utility as a pandemic vaccine.
自2013年3月首例人类感染病例以来，不断有H7N9病例报告，这凸显了潜在的大流行威胁。迫切需要针对这种病毒的高免疫原性疫苗，以保护缺乏保护性免疫力的易感人群。在本研究中，一种基于腺病毒载体、不依赖鸡蛋和佐剂的血凝素H7亚型流感疫苗（HAd-H7HA）在小鼠模型中表现出增强的细胞介导免疫以及血清抗体反应。最重要的是，这种疫苗提供了针对同源A/H7N9病毒攻击的完全保护，表明其作为大流行疫苗的潜在效用。
